– For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically… Read More
X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)… Read More
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing. The… Read More
Vancouver, BC – InMed Pharmaceuticals Inc. a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, announced an update regarding BayMedica LLC… Read More
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest… Read More
